Mucoadhesive Nanoformulations and Their Potential for Combating COVID-19

Prasher, Parteek; Sharma, Mousmee

doi:10.2217/nnm-2021-0287

Cited by 13 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the encapsulation of immunogens in the mucoadhesive polymer nanoparticles afford a sustainable strategy for the intranasal delivery of vaccines aimed at capping viral infections such as COVID-19. [218,219] Note that the mucoadhesion behavior of materials in bulk and at the nanoscale can significantly differ. However, development of new measurement techniques for studying mucoadhesion at the nanoscale and the refinement of the existing method are still needed to address the fact that a substantial amount of information is still lacking in the literature.…”

Section: Future Perspectivesmentioning

confidence: 99%

Recent Advances in Mucoadhesive Interface Materials, Mucoadhesion Characterization, and Technologies

Bayer

2022

Adv Materials Inter

View full text Add to dashboard Cite

Mucoadhesion is an extremely important field of adhesion science and the comprehensive understanding and modulation of mucoadhesion can lead to lifesaving materials and technologies. For instance, deadly cases of COVID‐19 (SARS‐CoV‐2) cytokine storm are associated with viral adhesion and overproduction of mucus, which obstructs the airways. Mucin is the key polymeric compound that is known as a family of high molecular weight, heavily glycosylated proteins in epithelial tissues. Mucoadhesion can occur in many different ways such as receptor specific and charge interactions, covalent or noncovalent bonds. New mucin‐mimic polymers that replicate its beneficial traits can prevent biofilm formation and biofouling not only in biotechnology but also in membrane technologies. This review addresses the latest understandings related to mucin's role in wet adhesion considering different physiological conditions and shows how this translates into interfacial polymer adhesion. Advances in mucoadhesion measurement techniques including the rheological aspects of polymer–mucin adhesive interactions are presented. Specific mucoadhesive systems are discussed such as hydrogel mucoadhesion, catechol/dopamine functionalization, and polymeric nanoparticles. This overview may expand the current understanding of mucoadhesion between soft materials but also contributes to elastocapillary phenomena in soft materials design and applications such as new membranes, drugs, pharmaceutical devices, and lubricated surfaces.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Recent Advances in Mucoadhesive Interface Materials, Mucoadhesion Characterization, and Technologies

Bayer

2022

Adv Materials Inter

View full text Add to dashboard Cite

show abstract

“…Mucins contain antimicrobial lactoferrin, lysozyme and salivary agglutinin that offer antiviral properties under optimal physiological conditions to sustain homeostasis. The airway epithelia, consisting of an outer gel-forming mucin layer and an inner layer of membrane-anchored mucins, serve as a potential binding site for the attacking pathogens and may facilitate the membrane fusion and cellular transit of SARS-CoV-2 [ 1 ]. When the viral load is high, overproduction of mucins becomes problematic as it impedes the lumen of the respiratory tract and limits optimal airflow.…”

mentioning

confidence: 99%

“…When the viral load is high, overproduction of mucins becomes problematic as it impedes the lumen of the respiratory tract and limits optimal airflow. Furthermore, the hypersecretion of mucins causes ciliary dysfunction that thwarts respiratory clearance, manifesting as chronic obstructive pulmonary disease, asthma and ciliary dyskinesia that further aggravate the COVID-19 symptoms [ 1 ]. The primary symptoms pertaining to the SARS-CoV-2-mediated cytokine storm involve hypersecretion of mucins, which potentially triggers various inflammatory pathways contributing toward COVID-19 pathogenesis [ 1 ].…”

mentioning

confidence: 99%

“…Furthermore, the hypersecretion of mucins causes ciliary dysfunction that thwarts respiratory clearance, manifesting as chronic obstructive pulmonary disease, asthma and ciliary dyskinesia that further aggravate the COVID-19 symptoms [ 1 ]. The primary symptoms pertaining to the SARS-CoV-2-mediated cytokine storm involve hypersecretion of mucins, which potentially triggers various inflammatory pathways contributing toward COVID-19 pathogenesis [ 1 ]. The occurrence of mucins in the bronchoalveolar lavage fluid and lung epithelial cells of COVID-19 patients further supports their role in COVID-19 pathophysiology.…”

mentioning

confidence: 99%

“…It is apparent that the COVID-19 management paradigm necessitates the development of novel delivery systems that successfully penetrate the mucus barrier to reach the underlying morbid tissues for delivering an optimal healing effect. Similarly, therapeutic formulations with mucoadhesive properties prolong the drug release to the target site, which lowers the dosing frequency, maintains an optimal therapeutic concentration of the drug at the target site and hence improves patient compliance [ 1 ]. In this commentary, we emphasize targeting the hypersecretion of mucins for containing the COVID-19 pandemic.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Targeting Mucin Hypersecretion in COVID-19 Therapy

Prasher

Sharma

2022

Future Med. Chem.

Self Cite

View full text Add to dashboard Cite

Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi‐Drug Delivery Platform

Butnarasu

Petrini

Bracotti

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Mucus is a complex barrier for pharmacological treatments and overcoming it is one of the major challenges faced during transmucosal drug delivery. To tackle this issue, a novel class of glycosylated nanoparticles, named "mucosomes," which are based on the most important protein constituting mucus, the mucin, is introduced. Mucosomes are designed to improve drug absorption and residence time on the mucosal tissues. Mucosomes are produced (150-300 nm), functionalized with glycans, and loaded with the desired drug in a single one-pot synthetic process and, with this method, a wide range of small and macro molecules can be loaded with different physicochemical properties. Various in vitro models are used to test the mucoadhesive properties of mucosomes. The presence of functional glycans is indicated by the interaction with lectins. Mucosomes are proven to be storable at 4 °C after lyophilization, and administration through a nasal spray does not modify the morphology of the mucosomes. In vitro and in vivo tests indicate mucosomes do not induce adverse effects under the investigated conditions. This study proposes mucosomes as a ground-breaking nanosystem that can be applied in several pathological contexts, especially in mucus-related disorders.

show abstract

Mucoadhesive Nanoformulations and Their Potential for Combating COVID-19

Cited by 13 publications

References 20 publications

Recent Advances in Mucoadhesive Interface Materials, Mucoadhesion Characterization, and Technologies

Recent Advances in Mucoadhesive Interface Materials, Mucoadhesion Characterization, and Technologies

Targeting Mucin Hypersecretion in COVID-19 Therapy

Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi‐Drug Delivery Platform

Contact Info

Product

Resources

About